Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Everolimus/lenvatinib

Various toxicities folloiwng off label use

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Calio A, et al. mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy. Virchows Archiv: an international journal of pathology 483 : 821-833, Jan 2023. Available from: URL: https://dx.doi.org/10.1007/s00428-023-03688-2 Calio A, et al. mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy. Virchows Archiv: an international journal of pathology 483 : 821-833, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​1007/​s00428-023-03688-2
Metadaten
Titel
Everolimus/lenvatinib
Various toxicities folloiwng off label use
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57462-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Pemetrexed

Case report

Bevacizumab